Sugi Predict

Sugi Predict / Compounds / SCHEMBL16899341

SCHEMBL16899341

SCHEMBL16899341

Cc1cc(B(O)O)cnc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 2/20 0.49
▸ GPR119 Q8TDV5 5/20 0.44
▸ KIT P10721 2/20 0.44
▸ CKS1B P61024 2/20 0.44
▸ SKP1 P63208 2/20 0.44
▸ SKP2 Q13309 2/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NR1H2 P55055 1/20 0.42
▸ NR1H3 Q13133 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GBA1 P04062 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366741 0.85 RET (0.50) RETGPR119KITCKS1BSKP1
SCHEMBL3390869 0.83 RET (0.49) RETGPR119KITCKS1BSKP1
SCHEMBL908053 0.83 RET (0.49) RETGPR119KITCKS1BSKP1
SCHEMBL30851276 0.82 MEN1 (0.61) RETGPR119KITCKS1BSKP1
SCHEMBL10317392 0.82 GBA1 (0.48) RETGPR119KITCKS1BSKP1
SCHEMBL2365916 0.82 MEN1 (0.61) RETGPR119KITCKS1BSKP1
SCHEMBL3171199 0.81 MAPT (0.59) RETGPR119KITCKS1BSKP1
SCHEMBL2560476 0.81 GPR119 (0.58) GPR119CKS1BSKP1SKP2MAPT
SCHEMBL2366752 0.81 GPR119 (0.47) RETGPR119KITCKS1BSKP1
SCHEMBL2365638 0.81 RET (0.47) RETGPR119KITCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 — — US disclosed
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. 2025-01-02 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed
WO-2015104677-A1 HETEROCYCLIC COMPOUNDS AS EZH2 INHIBITORS Piramal Enterprises Limited (IN) 2015-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 RET 3847/4885GPR119 4141/4885KIT 3464/4885
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS SSB, IDO1, IDO2 RET 4544/4885GPR119 1406/4885KIT 988/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 RET 3847/4885GPR119 4141/4885KIT 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.